Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs

BACKGROUND: Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L‐asparaginase (L‐ASP) has not been studied. HYPOTHESIS/OBJECTIVES: To evaluate the safety...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Vet Intern Med
Main Authors: Cawley, Jacob R., Wright, Zachary M., Meleo, Karri, Post, Gerald S., Clifford, Craig A., Vickery, Kathryn R., Vail, David M., Bergman, Philip J., Thamm, Douglas H.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Assuntos:
SMALL ANIMAL
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7096650/
https://ncbi.nlm.nih.gov/pubmed/32064697
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jvim.15723
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares